Navigation Links
Encorium Announces NASDAQ Panel Decision to Delist Common Stock; Announces Changes to its Board of Directors
Date:10/22/2010

customers are not definitive until fully negotiated contracts are executed by the parties; (xv) our backlog may not be indicative of future results and may not generate the revenues expected; (xvi) uncertainties regarding the availability of additional capital; (xvi) uncertainties regarding the execution of change orders by our clients for work already performed; and (xvi) uncertainties regarding our ability to integrate the business of Progenitor, which was acquired in July, 2010. You should not place undue reliance on any forward-looking statement. We undertake no obligation to publicly release the result of any revision of these forward-looking statements to reflect events or circumstances after the date they are made or to reflect the occurrence of unanticipated events. Please refer to the section entitled "Risk Factors" in the Company Annual Report on Form 10-K for the year ended December 31, 2009 and the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2010.

www.encorium.com


'/>"/>
SOURCE Encorium Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Encorium Appoints David Ginsberg President and Chief Executive Officer, Announces Changes to the Board of Directors
2. Encorium Reports Third Quarter 2008 Financial Results
3. Encorium Announces Receipt of Letter from Nasdaq Regarding its Third Quarter 2008 Form 10-Q Filing
4. Encorium Group Signs $3.1 Million of New Business Contracts Including an Extension of a Current U.S. Oncology Clinical Trial with a Major Pharmaceutical Company
5. Encorium Group Signs Approximately $2.0 Million of New Business Contracts
6. Encorium Named as Finalist for the Second Annual Vaccine Industry Excellence Award
7. Professor Hanna Nohynek Joins Encorium as Head Consultant of its Clinical Vaccine Research Team
8. Encorium Group Updates Expected Timeframe with Respect to the Sale of its U.S. Business
9. Encorium Group Completes Sale of its U.S. Business to Pierrel Research USA; Announces Management Changes
10. Encorium Reports Second Quarter 2009 Financial Results
11. Encorium Announces Receipt of Letters from Nasdaq Regarding its Second Quarter 2009 Form 10-Q Filing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... China Biologic Products, Inc. (NASDAQ: CBPO, ... integrated plasma-based biopharmaceutical company in China ... Shandong Taibang Biological Products Co. Ltd., has received ... Food and Drug Administration (the "CFDA") for its ... in the Company,s public filings, the CFDA inspected ...
(Date:12/24/2014)... 2014  Rock Creek Pharmaceuticals, Inc., (NASDAQ: ... Clinical Trial Application (CTA) with the United ... seeking regulatory approval to initiate clinical trials for the ... Contingent on the Company receiving CTA regulatory approval, ... to assess the safety, tolerability and dose escalation of ...
(Date:12/22/2014)... 22, 2014 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: ... focused on the development of autologous cell therapies, announced ... University of Calgary in conjunction with co-authors from Kyoto ... validates the company,s ongoing clinical research using dermal sheath ... baldness. The paper entitled " Hair Follicle ...
(Date:12/22/2014)... 22, 2014 The American ... of original research, reviews and editorials addressing developments ... practice, today published a provocative article exploring the ... progression and potential treatment of prostate cancer. ... and proposes the possibility that there could be ...
Breaking Biology Technology:China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4
... the universities in the resund Region University of ... together with MC2 at Chalmers University of Technology and ... up a network for co-operation within nanotechnology. , ... , Used efficiently, knowledge on nanotechnology will have ...
... CV Therapeutics,Inc. (Nasdaq: CVTX ) announced ... the Company issued new inducement stock options to,14 ... connection,with its commercialization efforts in the United States. ... 23,600 shares of common,stock and are classified as ...
... Less Than 100,000 Additional "FOR" Votes Required for Integra ... ISOT ) ("IsoTis"), an orthobiologics company, today reported ... the acquisition of,IsoTis by Integra LifeSciences Holdings Corporation (NASDAQ: ... of merger dated as of August,6, 2007. Today,s ...
Cached Biology Technology:CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350 2IsoTis Reports Status of Merger Vote 2IsoTis Reports Status of Merger Vote 3IsoTis Reports Status of Merger Vote 4
(Date:12/22/2014)... 22, 2014 Research and Markets ... addition of the "The Global Watermarking ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... overview of the global digital media watermarking ... and monitor piracy by securely and invisibly ...
(Date:12/19/2014)... VIEW, Calif. , Dec. 18, 2014  23andMe, ... publication of a study that pinpoints fine-scale differences in ... United States . Since immigrants first ... the United States has served as a ... illuminates how American history and the ongoing mixing of ...
(Date:12/17/2014)... Dec. 15, 2014  HITLAB SM announced ... (GCP) audit to confirm its adherence to current ... accomplishment enables HITLAB to conduct regulated smart device ... principles for patient safety and research quality. ... access, quality, and delivery with innovative technology," said ...
Breaking Biology News(10 mins):The Global Watermarking and Fingerprinting Markets 223andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2
... have shown that male fallow deer, known as bucks, can call ... rut (peak of the mating season), and their efforts in calling, ... In this new study, published today (10 February) in the journal ... bucks listen to the sound quality of rival males, calls and ...
... stored in the western Pacific Ocean caused by an unprecedented ... responsible for the hiatus in surface warming observed over the ... journal Nature Climate Change indicates that the dramatic ... Ocean, causing more heat to be taken out of the ...
... people see a skunk, the reaction usually is "Eww," ... around, they often think "Aww." Why some animals ... to defend themselves against predators is the question that ... and Theodore Stankowich of California State University, Long Beach ...
Cached Biology News:Fight or flight? Vocal cues help deer decide during mating season 2Pacific trade winds stall global surface warming -- for now 2Social or stinky? New study reveals how animal defenses evolve 2
DITHIOTHREITOL, 150UMOL, 1 EA. Dithiothreitol (DTT), 0.1 M Solution:, *0.1 M solution of DTT in high purity dH2O., *0.2 m filtered., *Storage: -20C. Category: SEQUENASE....
... Dithiothreitol, 1 g. High ... convenient sample preparation that give ... disrupt cells and tissues.Clean up ... sample volumes. Accurately quantitate protein ...
ANTI 5-HYDROXYTRYPTOPHAN CONJ....
IMAGEQUANT 400 WKSTN, 1 EA. Category: ImageQuant CCD Imagers....
Biology Products: